Antidiabetic drugs
Also known as: antidiabetics, diabetes medications
Antidiabetic drugs are medications that lower blood glucose in diabetes mellitus. They include insulin and non-insulin agents such as metformin, sulfonylureas, GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, and thiazolidinediones.
Antidiabetic drugs treat diabetes mellitus by lowering blood glucose, each class through a different mechanism. Type 1 diabetes always requires insulin, since the pancreas no longer produces it; insulin products range from rapid-acting analogs taken with meals to long-acting basal insulins. Type 2 diabetes is usually managed first with non-insulin agents, adding insulin if glucose control deteriorates.
Metformin, a biguanide, is the typical first-line oral agent for type 2 diabetes: it decreases hepatic glucose production and improves insulin sensitivity without causing hypoglycemia or weight gain. Sulfonylureas (such as glipizide and glyburide) stimulate pancreatic beta cells to release insulin, which makes them effective but a common cause of hypoglycemia. Thiazolidinediones (pioglitazone) improve peripheral insulin sensitivity but can cause fluid retention.
Newer classes work through the incretin and renal pathways. GLP-1 receptor agonists (such as semaglutide and liraglutide) enhance glucose-dependent insulin release, slow gastric emptying, and promote weight loss. DPP-4 inhibitors (sitagliptin) prolong the action of endogenous incretins. SGLT2 inhibitors (empagliflozin, canagliflozin) block glucose reabsorption in the kidney, excreting glucose in urine, with added cardiovascular and renal benefits. Matching each class to its mechanism and signature side effects — hypoglycemia with sulfonylureas and insulin, GI upset with metformin and GLP-1 agonists, genitourinary infections with SGLT2 inhibitors — is the core skill.
Antidiabetics appear on both medical and pharmacy exams: the USMLE Step 1 tests mechanisms and adverse effects in pharmacology, while the PTCE tests drug names, classes, and common side effects among endocrine system medications.
Key takeaways
- Type 1 diabetes always requires insulin; type 2 diabetes typically starts with oral or injectable non-insulin agents.
- Metformin is the standard first-line oral agent and does not cause hypoglycemia; sulfonylureas stimulate insulin release and commonly do.
- GLP-1 receptor agonists enhance glucose-dependent insulin secretion and promote weight loss; DPP-4 inhibitors prolong incretin action.
- SGLT2 inhibitors excrete glucose through the urine and raise the risk of genitourinary infections.
- The USMLE Step 1 tests antidiabetic mechanisms and adverse effects, and the PTCE tests names, classes, and side effects.